Diagonal Bio AB (DIABIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Diagonal Bio AB (DIABIO) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.27 Million ≈ $-244.50K USD) by net assets (Skr26.97 Million ≈ $2.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Diagonal Bio AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Diagonal Bio AB - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Diagonal Bio AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Diagonal Bio AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diagonal Bio AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ilika plc
LSE:IKA
|
-0.202x |
|
Thunder Power Holdings, Inc.
NASDAQ:AIEV
|
-0.049x |
|
MEDCAW INVESTMENTS LS-01
F:U09
|
N/A |
|
HSS Hire Group PLC
LSE:HSS
|
0.141x |
|
Canyon Creek Food Company Ltd
V:CYF
|
-0.002x |
|
JAYDEN RESOURCES INC.
F:977
|
0.110x |
|
Darmi Bersaudara Tbk PT
JK:KAYU
|
0.001x |
|
Universal Partners Ltd
JSE:UPL
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Diagonal Bio AB (2020–2024)
The table below shows the annual cash flow conversion efficiency of Diagonal Bio AB from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see DIABIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr24.59 Million ≈ $2.65 Million |
Skr-13.77 Million ≈ $-1.48 Million |
-0.560x | -127.33% |
| 2023-12-31 | Skr21.25 Million ≈ $2.29 Million |
Skr-5.23 Million ≈ $-562.94K |
-0.246x | +51.22% |
| 2022-12-31 | Skr31.25 Million ≈ $3.36 Million |
Skr-15.77 Million ≈ $-1.70 Million |
-0.505x | -56.20% |
| 2021-12-31 | Skr33.87 Million ≈ $3.64 Million |
Skr-10.94 Million ≈ $-1.18 Million |
-0.323x | -1367.78% |
| 2020-12-31 | Skr8.89 Million ≈ $957.03K |
Skr226.67K ≈ $24.39K |
0.025x | -- |
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more